Literature DB >> 24681599

Net risk reclassification p values: valid or misleading?

Margaret S Pepe1, Holly Janes, Christopher I Li.   

Abstract

BACKGROUND: The Net Reclassification Index (NRI) and its P value are used to make conclusions about improvements in prediction performance gained by adding a set of biomarkers to an existing risk prediction model. Although proposed only 5 years ago, the NRI has gained enormous traction in the risk prediction literature. Concerns have recently been raised about the statistical validity of the NRI.
METHODS: Using a population dataset of 10000 individuals with an event rate of 10.2%, in which four biomarkers have no predictive ability, we repeatedly simulated studies and calculated the chance that the NRI statistic provides a positive statistically significant result. Subjects for training data (n = 420) and test data (n = 420 or 840) were randomly selected from the population, and corresponding NRI statistics and P values were calculated. For comparison, the change in the area under the receiver operating characteristic curve and likelihood ratio statistics were calculated.
RESULTS: We found that rates of false-positive conclusions based on the NRI statistic were unacceptably high, being 63.0% in the training datasets and 18.8% to 34.4% in the test datasets. False-positive conclusions were rare when using the change in the area under the curve and occurred at the expected rate of approximately 5.0% with the likelihood ratio statistic.
CONCLUSIONS: Conclusions about biomarker performance that are based primarily on a statistically significant NRI statistic should be treated with skepticism. Use of NRI P values in scientific reporting should be halted.

Mesh:

Substances:

Year:  2014        PMID: 24681599      PMCID: PMC3982889          DOI: 10.1093/jnci/dju041

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  29 in total

1.  Comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929).

Authors:  M S Pepe; Z Feng; J W Gu
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

2.  Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

3.  A note on the evaluation of novel biomarkers: do not rely on integrated discrimination improvement and net reclassification index.

Authors:  Jørgen Hilden; Thomas A Gerds
Journal:  Stat Med       Date:  2013-04-02       Impact factor: 2.373

4.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.

Authors:  E R DeLong; D M DeLong; D L Clarke-Pearson
Journal:  Biometrics       Date:  1988-09       Impact factor: 2.571

5.  Use and misuse of the receiver operating characteristic curve in risk prediction.

Authors:  Nancy R Cook
Journal:  Circulation       Date:  2007-02-20       Impact factor: 29.690

6.  Decision curve analysis: a novel method for evaluating prediction models.

Authors:  Andrew J Vickers; Elena B Elkin
Journal:  Med Decis Making       Date:  2006 Nov-Dec       Impact factor: 2.583

7.  Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model.

Authors:  Mitchell H Gail
Journal:  J Natl Cancer Inst       Date:  2009-06-17       Impact factor: 13.506

8.  Gauging the performance of SNPs, biomarkers, and clinical factors for predicting risk of breast cancer.

Authors:  Margaret S Pepe; Holly E Janes
Journal:  J Natl Cancer Inst       Date:  2008-07-08       Impact factor: 13.506

9.  Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association.

Authors:  Mark A Hlatky; Philip Greenland; Donna K Arnett; Christie M Ballantyne; Michael H Criqui; Mitchell S V Elkind; Alan S Go; Frank E Harrell; Yuling Hong; Barbara V Howard; Virginia J Howard; Priscilla Y Hsue; Christopher M Kramer; Joseph P McConnell; Sharon-Lise T Normand; Christopher J O'Donnell; Sidney C Smith; Peter W F Wilson
Journal:  Circulation       Date:  2009-04-13       Impact factor: 29.690

Review 10.  Net reclassification indices for evaluating risk prediction instruments: a critical review.

Authors:  Kathleen F Kerr; Zheyu Wang; Holly Janes; Robyn L McClelland; Bruce M Psaty; Margaret S Pepe
Journal:  Epidemiology       Date:  2014-01       Impact factor: 4.822

View more
  31 in total

1.  Application of net reclassification index to non-nested and point-based risk prediction models: a review.

Authors:  Laine E Thomas; Emily C O'Brien; Jonathan P Piccini; Ralph B D'Agostino; Michael J Pencina
Journal:  Eur Heart J       Date:  2019-06-14       Impact factor: 29.983

Review 2.  Immune biomarkers: the promises and pitfalls of personalized medicine.

Authors:  Joanna C D Willis; Graham M Lord
Journal:  Nat Rev Immunol       Date:  2015-03-27       Impact factor: 53.106

3.  Concordance measure and discriminatory accuracy in transformation cure models.

Authors:  Yilong Zhang; Yongzhao Shao
Journal:  Biostatistics       Date:  2018-01-01       Impact factor: 5.899

4.  Net Reclassification Index and Integrated Discrimination Index Are Not Appropriate for Testing Whether a Biomarker Improves Predictive Performance.

Authors:  Peter M Burch; Warren E Glaab; Daniel J Holder; Jonathan A Phillips; John-Michael Sauer; Elizabeth G Walker
Journal:  Toxicol Sci       Date:  2017-03-01       Impact factor: 4.849

5.  Prediction Model for Nodal Disease Among Patients With Non-Small Cell Lung Cancer.

Authors:  Francys C Verdial; David K Madtes; Billanna Hwang; Michael S Mulligan; Katherine Odem-Davis; Rachel Waworuntu; Douglas E Wood; Farhood Farjah
Journal:  Ann Thorac Surg       Date:  2019-01-30       Impact factor: 4.330

6.  A statistical challenge: developing tests for biomarker utility specific to the intended use.

Authors:  Steven J Skates
Journal:  J Natl Cancer Inst       Date:  2014-03-28       Impact factor: 13.506

Review 7.  Developing risk prediction models for kidney injury and assessing incremental value for novel biomarkers.

Authors:  Kathleen F Kerr; Allison Meisner; Heather Thiessen-Philbrook; Steven G Coca; Chirag R Parikh
Journal:  Clin J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 8.237

8.  Indoor tanning and the MC1R genotype: risk prediction for basal cell carcinoma risk in young people.

Authors:  Annette M Molinaro; Leah M Ferrucci; Brenda Cartmel; Erikka Loftfield; David J Leffell; Allen E Bale; Susan T Mayne
Journal:  Am J Epidemiol       Date:  2015-04-08       Impact factor: 4.897

9.  First things first: risk model performance metrics should reflect the clinical application.

Authors:  Kathleen F Kerr; Holly Janes
Journal:  Stat Med       Date:  2017-12-10       Impact factor: 2.373

10.  Challenges in Predicting Recurrence After Resection of Node-Negative Non-Small Cell Lung Cancer.

Authors:  Lucas W Thornblade; Michael S Mulligan; Katherine Odem-Davis; Billanna Hwang; Rachel L Waworuntu; Erika M Wolff; Larry Kessler; Douglas E Wood; Farhood Farjah
Journal:  Ann Thorac Surg       Date:  2018-07-19       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.